Comparative Pharmacology
Head-to-head clinical analysis: BESREMI versus INTRON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BESREMI versus INTRON A.
BESREMI vs INTRON A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BESREMI (ropeginterferon alfa-2b) is a recombinant interferon alfa-2b conjugated to a 40 kDa polyethylene glycol (PEG) moiety. It binds to interferon alpha receptors (IFNAR1/IFNAR2), activating JAK-STAT signaling, leading to expression of interferon-stimulated genes with antiproliferative, antiviral, and immunomodulatory effects. Specifically, it suppresses the proliferation of hematopoietic progenitor cells, reduces JAK2V617F allele burden, and normalizes blood counts in polycythemia vera.
Interferon alfa-2b exerts antiviral, antiproliferative, and immunomodulatory effects by binding to type I interferon receptors, activating JAK-STAT signaling, inducing expression of antiviral proteins (e.g., Mx proteins, 2',5'-oligoadenylate synthetase), and enhancing natural killer cell cytotoxicity.
Subcutaneous injection of 250 to 350 mcg once every two weeks, with titration based on platelet counts and tolerability.
3 million IU subcutaneously 3 times per week for chronic hepatitis C; 5-10 million IU subcutaneously 3 times per week for hairy cell leukemia.
None Documented
None Documented
Terminal half-life approximately 50-100 hours (mean 70 h) in healthy volunteers; in patients with polycythemia vera, half-life is 50-80 hours, supporting once-weekly dosing.
2–3 hours (subcutaneous), 3–8 hours (intramuscular); terminal elimination half-life is approximately 2–3 hours. Clinical context: short half-life necessitates frequent dosing (e.g., three times weekly) for sustained antiviral/antiproliferative effect.
Primarily renal (clearance 0.5 L/h/kg), with <1% excreted unchanged in urine; remainder metabolized via proteolysis to small peptides and amino acids.
Renal (primarily): ~70% unchanged in urine; biliary/fecal: minor (<10%).
Category C
Category C
Interferon
Interferon